#United States #New York #cancer therapy #Hoth Therapeutics #HT-KIT

Hoth Therapeutics Reports Positive Preclinical Safety Data for HT-KIT

Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company focused on advancing treatments for rare and inflammatory diseases, has announced encouraging findings from their latest preclinical studies on HT-KIT, a candidate aimed at targeting the c-KIT pathway in cancer therapy. This development signifies a critical step in the journey towards clinical trials, with significant implications for cancer treatment.

Study Overview

The preclinical study encompassed multiple doses and highlighted a clear dose-responsive effect on liver mass. Importantly, no observable toxicity or organ pathologies were reported, supporting HT-KIT’s favorable safety profile as the company gears up for regulatory submissions and toxicology testing.

Key Findings

• - Liver Weight Increase: The study observed an increase in liver weight from 1.11 grams at 0 mg/kg to 1.32 grams at 3.0 mg/kg, indicating pharmacological engagement with the targeted pathway.
• - Stable Organ Functionality: There were no adverse effects noted in the kidneys, spleen, or thymus, suggesting no off-target effects or systemic toxicity occurred during the testing.
• - Excellent Safety Profile: All treated animals showed a clean safety profile with no gross pathological damage or visible lesions, reinforcing the validity of HT-KIT's safety.

CEO Robb Knie expressed confidence in the results, stating, "These findings bolster our confidence in HT-KIT as we prepare for clinical trials. The evident safety signal combined with dose responsiveness provides a viable path forward."

What’s Next?

Hoth Therapeutics is now looking to initiate Good Laboratory Practice (GLP) toxicology studies. Following these studies, the company aims to submit an Investigational New Drug (IND) application, which is a critical step in the drug development process, marking the transition from lab testing to human trials.

About Hoth Therapeutics

Founded with the mission to develop innovative and effective therapies, Hoth Therapeutics strives to improve the quality of life for patients facing challenging health issues. With a focus on early-stage research and development, the company collaborates with scientists and medical professionals to explore and develop therapeutics that hold high potential for groundbreaking advancements in treatment options.

The results from the HT-KIT study underline the company's dedication to pushing the frontiers of oncology treatment through innovative solutions targeted at serious illnesses like cancer, and their forward-looking approach indicates a strong future ahead.

Hoth's strategic direction reflects a commitment to collaborating with key opinion leaders and the scientific community to ensure that they are on the cutting edge of therapeutic development.

For further information and future updates, interested individuals can visit Hoth Therapeutics’ Investor Relations page.